@TheStockerMan TheStockerMan
High-conviction long-only growth investor building AI-era valuation theses on a concentrated basket
Writes long-form fundamental and valuation theses on a conce
Grade = how their written analysis reads (A best). Trader score = how their last-20 timestamped calls performed vs SPY. · Analyst brief as of 2026-07-03.
Across their last 20 scored bets: 70% hit rate, +2.52% mean alpha, trader score +3.05. Their last-14d mentions, direction-adjusted, have moved +0.7% since posting (mean over 130 mentions with price data).
The author is concentrated in HIMS, ZETA, SOFI, OSCR, NBIS and AMD, while actively trading ASTS, CRWV, NBIS and IREN around pullbacks. Their distinctive read is that HIMS is a cheap multi-year consumer-health platform with GLP-1 and peptide catalysts, while ZETA and AI compute names are underpriced versus growth and partnership optionality. Late in the window, the clearest shift is trimming ASTS strength to add CRWV weakness while also buying fear in NBIS and IREN.
Conviction is concentrated in HIMS, ZETA and AI compute names, with repeated adds or bullish valuation work across HIMS, ZETA, SOFI, NBIS, IREN, CRWV and GRRR. The main flip is in ASTS: he started by adding pullbacks, then considered and disclosed trimming ASTS strength to buy CRWV weakness. HIMS and ZETA remain high-concentration longs with pump-risk flags because each dominates its theme signal count.
| date (PT) | ticker | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|---|
| 2026-07-02 | LMND | @TheStockerMan | +0.65 | Bull case for LMND reinsurance economics, improving metrics, AI scale, and path to profitability. | — | tweet ↗ |
| 2026-07-02 | HIMS | @TheStockerMan | +0.75 | Multi-year bullish thesis that HIMS can expand consumer healthcare categories and peptide optionality. | — | tweet ↗ |
| 2026-07-02 | HIMS | @TheStockerMan | +0.65 | Bullish HIMS platform thesis around peptides, FDA meeting, valuation, and NVO partnership. | — | tweet ↗ |
| 2026-07-02 | NVO | @TheStockerMan | +0.10 | Bullish HIMS platform thesis around peptides, FDA meeting, valuation, and NVO partnership. | — | tweet ↗ |
| 2026-07-02 | CRWV | @TheStockerMan | +0.70 | Trimmed ASTS strength and added more CRWV weakness. — Discloses trimming ASTS to buy CRWV weakness and gives bullish valuation/backlog thesis. | — | tweet ↗ |
| 2026-07-02 | ASTS | @TheStockerMan | +0.20 | Trimmed ASTS strength and added more CRWV weakness. — Discloses trimming ASTS to buy CRWV weakness and gives bullish valuation/backlog thesis. | — | tweet ↗ |
| 2026-07-02 | META | @TheStockerMan | +0.10 | Trimmed ASTS strength and added more CRWV weakness. — Discloses trimming ASTS to buy CRWV weakness and gives bullish valuation/backlog thesis. | — | tweet ↗ |
| 2026-07-02 | NVDA | @TheStockerMan | +0.10 | Buying the fear in NBIS and IREN. — Explicitly says buying fear in NBIS/IREN with ARR fair value ranges and AI compute thesis. | — | tweet ↗ |
| 2026-07-02 | IREN | @TheStockerMan | +0.80 | Buying the fear in NBIS and IREN. — Explicitly says buying fear in NBIS/IREN with ARR fair value ranges and AI compute thesis. | — | tweet ↗ |
| 2026-07-02 | META | @TheStockerMan | +0.15 | Buying the fear in NBIS and IREN. — Explicitly says buying fear in NBIS/IREN with ARR fair value ranges and AI compute thesis. | — | tweet ↗ |
| 2026-07-02 | NBIS | @TheStockerMan | +0.80 | Buying the fear in NBIS and IREN. — Explicitly says buying fear in NBIS/IREN with ARR fair value ranges and AI compute thesis. | — | tweet ↗ |
| 2026-07-02 | MSFT | @TheStockerMan | +0.10 | Buying the fear in NBIS and IREN. — Explicitly says buying fear in NBIS/IREN with ARR fair value ranges and AI compute thesis. | — | tweet ↗ |
| 2026-07-01 | HIMS | @TheStockerMan | +0.75 | Says he more than doubled HIMS position at $15 during panic. | -2.0% | tweet ↗ |
| 2026-07-01 | PLTR | @TheStockerMan | +0.15 | Bullish valuation and growth thesis for PATH and ZETA with sales, revenue and EBITDA metrics. | +2.8% | tweet ↗ |
| 2026-07-01 | PATH | @TheStockerMan | +0.65 | Bullish valuation and growth thesis for PATH and ZETA with sales, revenue and EBITDA metrics. | +1.4% | tweet ↗ |
Grade is our human read-worthiness rating; trader score is a rolling 20-bet hit-rate/alpha composite — different things, often disagreeing. “Since then” is direction-unaware in the table; the summary line above adjusts for which way they leaned.